MigraineNCT07847554
Validity and Reliability of the Greek WPAI:Migraine
An observational study of Migraine, run by National and Kapodistrian University of Athens at 1 site in Greece.
Trial summary
Migraine is a common neurological disorder that can substantially impair work productivity and daily functioning through both absenteeism and presenteeism. The Work Productivity and Activity Impairment Questionnaire for Migraine (WPAI:Migraine) is a brief patient-reported measure designed to assess migraine-related… Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Migraine
- How many people
- 60 participants
- Where
- 1 siteGreece
- Study dates
- 1 Nov 2026to 1 Jul 2027
- How long will I take part?
- 1 Week
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults aged 18-70 years with a diagnosis of episodic or chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), confirmed by a specialist neurologist. Participants will be recruited from the Specialized Headache Clinic of Aeginition Hospital in Greece.
Who may be able to join
- Diagnosis of migraine
- Age 18-70 years
- Ability to understand, read, write, and speak the Greek language
Who cannot join
- Presence of a headache disorder other than migraine
- History of systemic diseases (malignant, inflammatory, acute traumatic, infectious, surgical, neurological, psychiatric, or rheumatological conditions)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Dimos Mitsikostas, Neurologist, PhD contact
Greece1 site
National Kapodistrian University of Athens, Aeginition Hospital, Headache Clinic
Athens, Attica, 11528
Michalis Kodounis, Neurologist, PhD, +30 697 3600069, kodounis@gmail.com
About this study
Official title: Assessment of Work Productivity and Activities in Patients With Migraine Using the "WPAI (Work Productivity and Activity Impairment)" Questionnaire: Validity and Reliability Study of the Greek Version
Migraine is a common neurological disorder that can substantially impair work productivity and daily functioning through both absenteeism and presenteeism. The Work Productivity and Activity Impairment Questionnaire for Migraine (WPAI:Migraine) is a brief patient-reported measure designed to assess migraine-related impairment in work and daily activities. Although the questionnaire has demonstrated validity and reliability in other populations, a validated Greek version is currently unavailable. This study aims to evaluate the validity and reliability of the Greek version of the WPAI:Migraine in individuals with episodic or chronic migraine, thereby providing an appropriate tool for assessing migraine-related work productivity and functional impairment in the Greek population.
Read the detailed description
Migraine is one of the most common neurological disorders among working-age individuals worldwide and a major cause of lost work productivity. Migraine attacks not only cause pain and associated symptoms but also lead to work absenteeism, reduced productivity, and limitations in daily activities. A study including 31 countries showed that 52% of individuals with at least 4 migraine days per month experienced an overall reduction in work performance due to migraine, and that this was attributable more to presenteeism than absenteeism. The American Migraine Prevalence and Prevention Study reported that the cost of presenteeism was nearly three times that of absenteeism in patients with episodic migraine.
The Work Productivity and Activity Impairment Questionnaire (WPAI) is a brief and widely used patient-reported outcome measure that assesses the impact of chronic diseases on work performance. WPAI:Migraine, a migraine-specific version, has been found to be valid and reliable in American and Arabic populations of patients with episodic and chronic migraine. International Headache Society (IHS) guidelines for preventive treatment trials in episodic and chronic migraine recommend the use of the WPAI. Therefore, it is important to evaluate the impact of migraine not only through clinical parameters but also in terms of productivity and functioning.
In Greece, migraine studies have been conducted at the population level using pharmacological treatments and assessments. However, with regard to daily life and work productivity, there is currently no validated Greek WPAI:Migraine questionnaire available to assess migraine-related productivity loss. Availability of such a scale for the Greek migraine population is important for clinical applications, health-economics research, and evaluation of treatment outcomes.
Aim of the study - Hypotheses to be tested The aim of the present study is to investigate the validity and reliability of the Greek version of the WPAI:Migraine questionnaire in individuals with migraine and to determine whether it can be used as a valid and reliable tool for assessing work productivity and functioning in the Greek population.
Hypotheses:
Hypotheses:
- H0: The Greek version of the WPAI:Migraine is not valid and reliable for patients with migraine in the Greek population.
- H1: The Greek version of the WPAI:Migraine is valid and reliable for patients with migraine in the Greek population.
- Conditions
- Migraine
- Keywords
- migraine, headache, work productivity, absenteeism, presenteeism, disability, quality of life
- Medical subject headings
- Migraine Disorders, Headache
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with Migraine | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Greek Version of the Work Productivity and Activity Impairment Questionnaire for Migraine (WPAI:Migraine)
The validity and reliability of the Greek version of the WPAI:Migraine will be evaluated in patients with migraine. The questionnaire assesses work productivity and activity impairment over the previous 7 days, including absenteeism, presenteeism, overall work impairment, and activity impairment. Higher percentage scores indicate greater impairment.
Measured: Baseline and 7-14 days after baseline for test-retest reliability.
Secondary outcomes (4)
Migraine-Related Disability
igraine-related disability will be assessed using the MIDAS questionnaire, which evaluates disability over the previous 3 months. The total score is calculated from five items, with higher scores indicating greater migraine-related disability.
Measured: Baseline
Headache Impact
The impact of headache on daily functioning and quality of life will be assessed using the HIT-6. Total scores range from 36 to 78, with higher scores indicating greater headache impact.
Measured: Baseline
Migraine-Specific Quality of Life
Migraine-specific quality of life over the previous 4 weeks will be assessed using the MSQv2.1, which includes Role Function-Restrictive, Role Function-Preventive, and Emotional Function domains. Scores are transformed to a 0-100 scale, with higher scores indicating better migraine-specific quality of life.
Measured: Baseline
Headache Pain Intensity
Headache pain intensity will be assessed using the Visual Analog Scale, ranging from 0 (no pain) to 10 (worst imaginable pain), with higher scores indicating greater pain intensity.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2026
- Study start1 Nov 2026 (estimated)
- Primary completion1 Jun 2027 (estimated)
- Study completion1 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (17)Papers the sponsor has linked to this study.
- Other trials for MigraineStudies of the same condition, open and under way.
- More trials run by National and Kapodistrian University of AthensThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
- Target duration
- 1 Week
Sponsor and investigators
- Lead sponsor
- National and Kapodistrian University of Athens
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Michalis Kodounis, National and Kapodistrian University of Athens
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07847554
- Sponsor's protocol ID
- Approval Νο: 703, 3-6-2026
- Status last verified
- Oct 2026
- First submitted
- 22 Sep 2026
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) are not planned to be made publicly available. Data may be considered for sharing upon reasonable request and subject to applicable ethical and institutional requirements.
Publications
Ford JH, Ye W, Ayer DW, Mi X, Bhandari S, Buse DC, Lipton RB. Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine. J Patient Rep Outcomes. 2023 Apr 4;7(1):34. doi: 10.1186/s41687-023-00552-4.
PubMed 37016181Ishii R, Sakai F, Sano H, Nakai M, Koga N, Matsukawa M. Quality of life and work productivity and activity impairment among online survey respondents with migraine across a range of headache frequency. Front Neurol. 2024 Jul 9;15:1440733. doi: 10.3389/fneur.2024.1440733. eCollection 2024.
PubMed 39045427Martelletti P, Schwedt TJ, Lanteri-Minet M, Quintana R, Carboni V, Diener HC, Ruiz de la Torre E, Craven A, Rasmussen AV, Evans S, Laflamme AK, Fink R, Walsh D, Dumas P, Vo P. My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018 Nov 27;19(1):115. doi: 10.1186/s10194-018-0946-z.
PubMed 30482181Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, Reed M, Lipton RB. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009 Apr;49(4):498-508. doi: 10.1111/j.1526-4610.2009.01369.x. Epub 2009 Feb 25.
PubMed 19245386Albilali A, Almutawa RA, Almusahel EA, Almutawa RA, Almutawa NA, Almutawa FM, AlAujan S, AlMalag HM. Psychometric Validation of the Arabic Version of the WPAI:Migraine Questionnaire in Patients with Migraine. Neurol Int. 2025 Dec 12;17(12):202. doi: 10.3390/neurolint17120202.
PubMed 41441221Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018 Apr;38(5):815-832. doi: 10.1177/0333102418758283. Epub 2018 Mar 4.
PubMed 29504482Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Houle TT, Hoek TCVD, Martinelli D, Terwindt GM; International Headache Society Clinical Trials Committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020 Sep;40(10):1026-1044. doi: 10.1177/0333102420941839. Epub 2020 Jul 28.
PubMed 32722936Axiotidou M, Karapanayiotides T, Papakonstantinou D. Exploring the professional and personal impact of migraine: a cross-sectional study in Greece. J Oral Facial Pain Headache. 2025 Jun;39(2):124-136. doi: 10.22514/jofph.2025.031. Epub 2025 Jun 12.
PubMed 41070540Vikelis M, Kourlaba G, Barba L, Bilias K, Barbalia E, Solakidi A, Trafalis D, Lioliou K, Zyga S, Karapanayiotides T, Mitsikostas DD. The unmet needs in management, the treatment gap and the burden of migraine in Greece: a Delphi consensus and focus group study from patients' perspective. Front Neurol. 2025 Feb 24;16:1558014. doi: 10.3389/fneur.2025.1558014. eCollection 2025.
PubMed 40066304Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202. No abstract available.
PubMed 29368949Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983 Sep;17(1):45-56. doi: 10.1016/0304-3959(83)90126-4.
PubMed 6226917Oikonomidi T, Vikelis M, Artemiadis A, Chrousos GP, Darviri C. Reliability and Validity of the Greek Migraine Disability Assessment (MIDAS) Questionnaire. Pharmacoecon Open. 2018 Mar;2(1):77-85. doi: 10.1007/s41669-017-0034-3.
PubMed 29464670Martin M, Blaisdell B, Kwong JW, Bjorner JB. The Short-Form Headache Impact Test (HIT-6) was psychometrically equivalent in nine languages. J Clin Epidemiol. 2004 Dec;57(12):1271-8. doi: 10.1016/j.jclinepi.2004.05.004.
PubMed 15617953Giannouli E, Giannouli E, Alexoudi A, Arvaniti C, Fakas N, Constantinidis TS, Kouremenos E, Mitsikostas DD; Hellenic Headache Society. Validity and reliability of the Greek Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.1-GR). J Patient Rep Outcomes. 2024 Jul 15;8(1):72. doi: 10.1186/s41687-024-00762-4.
PubMed 39007966Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993 Nov;4(5):353-65. doi: 10.2165/00019053-199304050-00006.
PubMed 10146874
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Work Productivity and Activities in Patients With Migraine Using the "WPAI (Work Productivity and Activity Impairment)" Questionnaire: Validity and Reliability Study of the Greek Version
- ClinicalTrials.gov ID
- NCT07847554
- Acronym / sponsor ID
- Approval Νο: 703, 3-6-2026
- Conditions
- Migraine
- Keywords
- migraine, headache, work productivity, absenteeism, presenteeism, disability, quality of life
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- National and Kapodistrian University of AthensUniversity, hospital or other
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 1 Jun 2027 (estimated)
- Study completion
- 1 Jul 2027 (estimated)
- First posted
- 29 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Migraine is a common neurological disorder that can substantially impair work productivity and daily functioning through both absenteeism and presenteeism. The Work Productivity and Activity Impairment Questionnaire for Migraine (WPAI:Migraine) is a brief patient-reported measure designed to assess migraine-related impairment in work and daily activities. Although the questionnaire has demonstrated validity and reliability in other populations, a validated Greek version is currently unavailable. This study aims to evaluate the validity and reliability of the Greek version of the WPAI:Migraine in individuals with episodic or chronic migraine, thereby providing an appropriate tool for assessing migraine-related work productivity and functional impairment in the Greek population.
Detailed description
Migraine is one of the most common neurological disorders among working-age individuals worldwide and a major cause of lost work productivity. Migraine attacks not only cause pain and associated symptoms but also lead to work absenteeism, reduced productivity, and limitations in daily activities. A study including 31 countries showed that 52% of individuals with at least 4 migraine days per month experienced an overall reduction in work performance due to migraine, and that this was attributable more to presenteeism than absenteeism. The American Migraine Prevalence and Prevention Study reported that the cost of presenteeism was nearly three times that of absenteeism in patients with episodic migraine.
The Work Productivity and Activity Impairment Questionnaire (WPAI) is a brief and widely used patient-reported outcome measure that assesses the impact of chronic diseases on work performance. WPAI:Migraine, a migraine-specific version, has been found to be valid and reliable in American and Arabic populations of patients with episodic and chronic migraine. International Headache Society (IHS) guidelines for preventive treatment trials in episodic and chronic migraine recommend the use of the WPAI. Therefore, it is important to evaluate the impact of migraine not only through clinical parameters but also in terms of productivity and functioning.
In Greece, migraine studies have been conducted at the population level using pharmacological treatments and assessments. However, with regard to daily life and work productivity, there is currently no validated Greek WPAI:Migraine questionnaire available to assess migraine-related productivity loss. Availability of such a scale for the Greek migraine population is important for clinical applications, health-economics research, and evaluation of treatment outcomes.
Aim of the study - Hypotheses to be tested The aim of the present study is to investigate the validity and reliability of the Greek version of the WPAI:Migraine questionnaire in individuals with migraine and to determine whether it can be used as a valid and reliable tool for assessing work productivity and functioning in the Greek population.
Hypotheses:
Hypotheses:
- H0: The Greek version of the WPAI:Migraine is not valid and reliable for patients with migraine in the Greek population.
- H1: The Greek version of the WPAI:Migraine is valid and reliable for patients with migraine in the Greek population.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 1 Week
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with Migraine | – | – |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults aged 18-70 years with a diagnosis of episodic or chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), confirmed by a specialist neurologist. Participants will be recruited from the Specialized Headache Clinic of Aeginition Hospital in Greece.
Key inclusion criteria (3 listed)
- Diagnosis of migraine
- Age 18-70 years
- Ability to understand, read, write, and speak the Greek language
Key exclusion criteria (2 listed)
- Presence of a headache disorder other than migraine
- History of systemic diseases (malignant, inflammatory, acute traumatic, infectious, surgical, neurological, psychiatric, or rheumatological conditions)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Greek Version of the Work Productivity and Activity Impairment Questionnaire for Migraine (WPAI:Migraine)
Time frame: Baseline and 7-14 days after baseline for test-retest reliability.
The validity and reliability of the Greek version of the WPAI:Migraine will be evaluated in patients with migraine. The questionnaire assesses work productivity and activity impairment over the previous 7 days, including absenteeism, presenteeism, overall work impairment, and activity impairment. Higher percentage scores indicate greater impairment.
4 secondary outcomes
Migraine-Related Disability
Time frame: Baseline
Headache Impact
Time frame: Baseline
Migraine-Specific Quality of Life
Time frame: Baseline
Headache Pain Intensity
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- Background: PubMed 37016181Ford JH, Ye W, Ayer DW, Mi X, Bhandari S, Buse DC, Lipton RB. Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine. J Patient Rep Outcomes. 2023 Apr 4;7(1):34. doi: 10.1186/s41687-023-00552-4.
- Background: PubMed 39045427Ishii R, Sakai F, Sano H, Nakai M, Koga N, Matsukawa M. Quality of life and work productivity and activity impairment among online survey respondents with migraine across a range of headache frequency. Front Neurol. 2024 Jul 9;15:1440733. doi: 10.3389/fneur.2024.1440733. eCollection 2024.
- Background: PubMed 30482181Martelletti P, Schwedt TJ, Lanteri-Minet M, Quintana R, Carboni V, Diener HC, Ruiz de la Torre E, Craven A, Rasmussen AV, Evans S, Laflamme AK, Fink R, Walsh D, Dumas P, Vo P. My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018 Nov 27;19(1):115. doi: 10.1186/s10194-018-0946-z.
- Background: PubMed 19245386Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, Reed M, Lipton RB. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009 Apr;49(4):498-508. doi: 10.1111/j.1526-4610.2009.01369.x. Epub 2009 Feb 25.
- Background: PubMed 41441221Albilali A, Almutawa RA, Almusahel EA, Almutawa RA, Almutawa NA, Almutawa FM, AlAujan S, AlMalag HM. Psychometric Validation of the Arabic Version of the WPAI:Migraine Questionnaire in Patients with Migraine. Neurol Int. 2025 Dec 12;17(12):202. doi: 10.3390/neurolint17120202.
- Background: PubMed 29504482Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018 Apr;38(5):815-832. doi: 10.1177/0333102418758283. Epub 2018 Mar 4.
- Background: PubMed 32722936Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Houle TT, Hoek TCVD, Martinelli D, Terwindt GM; International Headache Society Clinical Trials Committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020 Sep;40(10):1026-1044. doi: 10.1177/0333102420941839. Epub 2020 Jul 28.
- Background: PubMed 41070540Axiotidou M, Karapanayiotides T, Papakonstantinou D. Exploring the professional and personal impact of migraine: a cross-sectional study in Greece. J Oral Facial Pain Headache. 2025 Jun;39(2):124-136. doi: 10.22514/jofph.2025.031. Epub 2025 Jun 12.
- Background: PubMed 40066304Vikelis M, Kourlaba G, Barba L, Bilias K, Barbalia E, Solakidi A, Trafalis D, Lioliou K, Zyga S, Karapanayiotides T, Mitsikostas DD. The unmet needs in management, the treatment gap and the burden of migraine in Greece: a Delphi consensus and focus group study from patients' perspective. Front Neurol. 2025 Feb 24;16:1558014. doi: 10.3389/fneur.2025.1558014. eCollection 2025.
- Background: PubMed 29368949Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202. No abstract available.
- Background: PubMed 6226917Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983 Sep;17(1):45-56. doi: 10.1016/0304-3959(83)90126-4.
- Background: PubMed 29464670Oikonomidi T, Vikelis M, Artemiadis A, Chrousos GP, Darviri C. Reliability and Validity of the Greek Migraine Disability Assessment (MIDAS) Questionnaire. Pharmacoecon Open. 2018 Mar;2(1):77-85. doi: 10.1007/s41669-017-0034-3.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data (IPD) are not planned to be made publicly available. Data may be considered for sharing upon reasonable request and subject to applicable ethical and institutional requirements.
Related trials for Migraine
RecruitingObservational study
Study of the Glymphatic System in Migraine
Migraine
Active, not recruiting
Clinical and Neurophysiological Effects of tDCS to Visual and Motor Cortex in Migraine
Migraine
Active, not recruiting
App-Based Migraine Treatment: The Health enSuite Study
Migraine, Migraine With Aura
Not yet recruiting
A Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals
Migraine Disorders
Recruiting
Marine Lipids Ease Painful TMD
Temporomandibular Disorder (TMD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dimos Mitsikostas, Neurologist, PhD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Migraine, run by National and Kapodistrian University of Athens at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Michalis Kodounis, Neurologist, PhD (+30 697 3600069, kodounis@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Greek Version of the Work Productivity and Activity Impairment Questionnaire for Migraine (WPAI:Migraine) (time frame: Baseline and 7-14 days after baseline for test-retest reliability.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07847554, which also lists 17 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.